These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25710167)

  • 1. Algorithm evolution for drug resistance prediction: comparison of systems for HIV-1 genotyping.
    Wagner S; Kurz M; Klimkait T;
    Antivir Ther; 2015; 20(6):661-5. PubMed ID: 25710167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
    De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
    Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand.
    Poonpiriya V; Sungkanuparph S; Leechanachai P; Pasomsub E; Watitpun C; Chunhakan S; Chantratita W
    J Virol Methods; 2008 Jul; 151(1):79-86. PubMed ID: 18462814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance.
    Liu L; May S; Richman DD; Hecht FM; Markowitz M; Daar ES; Routy JP; Margolick JB; Collier AC; Woelk CH; Little SJ; Smith DM
    AIDS; 2008 Apr; 22(7):835-9. PubMed ID: 18427201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.
    Di Giambenedetto S; Bacarelli A; Pinnetti C; Colafigli M; Prosperi M; Gatti G; Cauda R; De Luca A
    Scand J Infect Dis; 2007; 39(9):813-8. PubMed ID: 17701721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.
    Cotte L; Trabaud MA; Tardy JC; Brochier C; Gilibert RP; Miailhes P; Trépo C; André P
    J Med Virol; 2009 Apr; 81(4):672-7. PubMed ID: 19235860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
    Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX
    HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
    Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
    Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
    J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrepancies of HIV-1 reverse transcriptase resistance interpretation of insertions and deletions between two genotypic algorithms.
    López-Lopes GI; Lança AM; de Paula Ferreira JL; Souza LO; de Macedo Brígido LF
    Intervirology; 2013; 56(4):217-23. PubMed ID: 23689813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients.
    Vergne L; Snoeck J; Aghokeng A; Maes B; Valea D; Delaporte E; Vandamme AM; Peeters M; Van Laethem K
    FEMS Immunol Med Microbiol; 2006 Feb; 46(1):53-62. PubMed ID: 16420597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms.
    Champenois K; Bocket L; Deuffic-Burban S; Cotte L; André P; Choisy P; Yazdanpanah Y
    AIDS; 2008 May; 22(9):1087-9. PubMed ID: 18520355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of nine resistance interpretation systems for HIV-1 genotyping.
    Stürmer M; Doerr HW; Staszewski S; Preiser W
    Antivir Ther; 2003 Jun; 8(3):239-44. PubMed ID: 12924541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms.
    Kijak GH; Rubio AE; Pampuro SE; Zala C; Cahn P; Galli R; Montaner JS; Salomón H
    HIV Med; 2003 Jan; 4(1):72-8. PubMed ID: 12534963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.